Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for Arcutis Biotherapeutics (ARQT) over the last 4 years, with Q3 2025 value amounting to $449000.0.

  • Arcutis Biotherapeutics' Amortization of Deferred Charges fell 4387.5% to $449000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 169.93%. This contributed to the annual value of $5.4 million for FY2024, which is 3409.43% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Amortization of Deferred Charges stood at $449000.0, which was down 4387.5% from $431000.0 recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Amortization of Deferred Charges registered a high of $2.6 million during Q4 2024, and its lowest value of $392000.0 during Q1 2022.
  • In the last 4 years, Arcutis Biotherapeutics' Amortization of Deferred Charges had a median value of $994000.0 in 2023 and averaged $889000.0.
  • In the last 5 years, Arcutis Biotherapeutics' Amortization of Deferred Charges soared by 15541.34% in 2024 and then crashed by 5866.53% in 2025.
  • Arcutis Biotherapeutics' Amortization of Deferred Charges (Quarter) stood at $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then soared by 155.41% to $2.6 million in 2024, then tumbled by 82.7% to $449000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $449000.0 for Q3 2025, versus $431000.0 for Q2 2025 and $415000.0 for Q1 2025.